Ms. Pope has more than 30 years of experience in Human Resources, with over 20 years in the pharmaceutical industry.

Most recently, Ms. Pope was the SVP of Human Resources at Array BioPharma where she helped to build and transform the organization in preparation for the first commercial product launch. Prior to her role at Array, Ms. Pope spent 2 ½ years at IDEX Corporation as a Group Vice President of HR and over 15 years at Hospira in a variety of human resources roles of increasing scope and responsibility.

Ms. Pope received her undergraduate degree in Marketing and Human Resources from the University of Iowa.

Mr. Graham serves as Chief Legal Officer and has over 25 years of legal, compliance and executive management experience in publicly and privately held pharmaceutical and medical device companies.

Most recently, from 2015 until its sale to Halozyme Therapeutics, Inc. in 2022, Mr. Graham served as Executive Vice President, General Counsel, Chief Compliance Officer, Human Resources and Secretary for Antares Pharma, Inc., a commercial stage specialty pharmaceutical and combination product company. Prior to Antares, Mr. Graham served as Executive Vice President, General Counsel, Chief Compliance Officer and Global Human Resources for Delcath Systems, Inc., an interventional oncology company focused on liver cancers. Earlier in his career, Mr. Graham served in various senior legal and executive leadership positions at ACIST Medical Systems, Inc., a subsidiary of Bracco, SpA, E-Z-EM, Inc. and AngioDynamics, Inc.

Mr. Graham earned his JD at Yeshiva University’s Benjamin N. Cardozo School of Law and his BA in Political Science at the University of Wisconsin-Madison.

David Ege is the Chief Technical Officer of ADCT. He has more than 20 years of experience in the pharmaceutical industry, with a focus in biologics, vaccines and novel modalities.

Prior to joining ADCT Dr. Ege was CTO, head of Process Development, Quality and Supply at Seres Therapeutics since 2020. He began his career at Merck in 2003, serving in a variety of technical and leadership roles in R&D, manufacturing and supply chain, in the U.S. and Switzerland. From 2015-2019, Dr. Ege served as Executive Director of Vaccines & Biologics Manufacturing at Merck’s plant in Elkton, VA where he led bulk manufacturing operations for the Gardasil^® and Gardasil9^® cervical cancer vaccines, as well as adjuvants and Cancidas^® – a broad-based anti-fungal medicine made by fermentation. He has contributed to the successful first-in-class licensure and launch of cervical cancer vaccines, Gardasil^® (2006) and Gardasil9^® (2014), the breakthrough cancer immunotherapy, Keytruda^®.

He graduated summa cum laude from Princeton with a BSE in chemical engineering and earned his PhD in chemical engineering from the University of Pennsylvania.

Dr. van Berkel has more than 20 years of experience in the biotech industry, specializing in the development of antibody-based therapeutics.

Prior to joining ADC Therapeutics, Dr. van Berkel spent more than 9 years with Genmab in various roles, including Vice President of Antibody Technology and Vice President of CMC R&D.

Dr. van Berkel has a chemistry degree from the University of Nijmegen, The Netherlands (1991) and did his thesis at the University of Leiden, The Netherlands (1998).

Ms. Harrington-Smith joined ADC Therapeutics in November 2022 with over 20 years of experience in the pharmaceutical industry. Most recently, she served as Chief Commercial Officer at ImmunoGen.

Prior to joining ImmunoGen, Ms. Harrington-Smith held roles of increasing responsibility at Novartis Pharmaceuticals including US Commercial Head of Hematology, where she led the commercial teams responsible for a portfolio of therapies in both malignant and non-malignant hematologic diseases including acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, idiopathic thrombocytopenic purpura, sickle cell disease, and paroxysmal nocturnal hemoglobinuria. Prior to this role, she was responsible for the commercial launch of Kymriah^®, the first CAR-T-cell therapy for the treatment of diffuse large B-cell lymphoma and pediatric acute lymphoblastic leukemia, building the management, sales, marketing, and market access teams. She currently serves on the board of directors of eFFECTOR Therapeutics.

Ms. Harrington-Smith received a BA from Williams College and an MBA from the Kenan-Flagler Business School at the University of North Carolina.

Mohamed Zaki, MD, PhD joined ADC Therapeutics in January 2023 bringing over 20 years of global biopharmaceutical experience in hematology and oncology drug development.

Dr. Zaki joined ADC Therapeutics from Abbvie where he spent the last four years, most recently as Vice President and Global Head of Oncology Development. Prior to Abbvie, he spent nine years at Celgene in increasingly senior roles in oncology and hematology development. Previously, Dr. Zaki worked in clinical development at Sanofi-Aventis and Centocor Inc., a subsidiary of Johnson & Johnson.

Dr. Zaki earned his MD and MS at Ain Shams University School of Medicine in Cairo, Egypt and his PhD from the University of Pennsylvania and Ain Shams University School of Medicine in a joint degree program. He also served on the faculty of both institutions and was a practicing physician earlier in his career.

Jose “Pepe” Carmona joined ADC Therapeutics as Chief Financial Officer in December 2022 bringing over 20 years of financial experience in the biotechnology and pharmaceutical industries.

Prior to ADC Therapeutics, Mr. Carmona was the CFO at Rubius Therapeutics, a biopharmaceutical company engineering red blood cells to create a new class of cellular medicines for cancer and autoimmune diseases. Before joining Rubius Therapeutics, he was the CFO of Radius Health, a global commercial company specializing in bone health. Prior to Radius Health, he served as CFO of Innocoll Holdings PLC, acquired by Gurnet Point L.P. Previously, Mr. Carmona spent 12 years at Novartis AG in numerous global and regional financial management positions across the business, including serving as CFO for divisions in Europe, North America and Latin America. He serves on the board of directors at Senda Biosciences and Hotspot Therapeutics.

Mr. Carmona holds an MBA from the Columbia Business School and received his BS in Civil Engineering from Universidad Tecnica Federico Santa Maria in Valparaiso, Chile.